Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Fenocchio, Elisabetta; Depetris, Ilaria; Campanella, Delia; Garetto, Lucia; Schianca, Fabrizio; Galizia, Danilo; Grignani, Giovanni; Aglietta, Massimo; Leone, Francesco
• Is Part Of: BMC cancer. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 5
• Publication Date: 2016-12
• Subjects: Gemcitabine -- Pancreatic cancer -- Pulmonary toxicity -- Imatinib mesylate -- Treatment outcome; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-016-2833-9
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Gemcitabine is currently the standard chemotherapy for the adjuvant treatment of pancreatic cancer. This chemotherapeutic agent is generally well-tolerated, myelosuppression and gastrointestinal toxicity being common side effects. Nevertheless, gemcitabine-induced pulmonary toxicity has been rarely reported. Despite its low incidence, the spectrum of pulmonary injury is wide, including potentially fatal conditions. We report a case of acute interstitial pneumonia related to gemcitabine, completely solved with Imatinib Mesylate (IM). Case presentation The patient was a 69-year-old man, who developed a hypoxemic respiratory distress during adjuvant treatment with gemcitabine for stage IIA pancreatic cancer. The nonspecific diffuse alveolar involvement found on computed tomography (CT), together with the negative tests for infectious aetiology and the continuing severe respiratory failure despite a long course of broad-spectrum therapy, suggested gemcitabine-induced acute pneumonia as the most likely diagnosis. Thus, after the failure of steroids and all other conventional therapies, the patient was treated with imatinib mesylate on the basis of its activity in the management of graft-versus-host-induced lung fibrosis. A follow-up CT scan of chest one month later showed complete resolution of pneumonia. Conclusion Despite the low frequency of serious pulmonary toxicity, gemcitabine widespread use warns clinicians to consider this life-threatening toxicity. The favourable clinical outcome with IM treatment was remarkable, warranting additional study of IM in the treatment of lung fibrosis.